A COMPARATIVE CLINICAL AND COST-EFFECTIVENESS EVALUATION OF GEFITINIB AND ERLOTINIB IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER

被引：0
|
作者：
Lopes, Gilberto D. L., Jr. [1 ]
Segel, Joel [2 ]
Tan, Daniel [3 ]
Do, Young [2 ]
Mok, Tony [4 ]
Finkelstein, Eric [2 ]
机构：
[1] Johns Hopkins Univ, Sch Med, Johns Hopkins Singapore Int Med Ctr, Singapore, Singapore
[2] Hlth Serv & Outcomes Res, Duke Nus, Singapore
[3] Natl Canc Ctr Singapore, Singapore, Singapore
[4] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
Lung cancer; gefitinib; erlotinib; Cost-effectiveness;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1306 / S1307
页数：2
相关论文
共 50 条
  • [1] Gefitinib or Erlotinib in the Treatment of Advanced Non-small Cell Lung Cancer
    Shao, Yu-Yun
    Lin, Chia-Chi
    Yang, Chih-Hsin
    [J]. DISCOVERY MEDICINE, 2010, 9 (49) : 538 - 545
  • [2] COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN ROMANIA
    Ciuleanu, T. E.
    Dediu, M.
    Minea, L. N.
    Baculea, S.
    Szkultecka-Debek, M.
    [J]. VALUE IN HEALTH, 2010, 13 (03) : A38 - A38
  • [3] COST-EFFECTIVENESS OF ERLOTINIB IN THE TREATMENT OF ADVANCED NON SMALL CELL LUNG CANCER IN CHINA
    Chen, W.
    Sheng, F.
    Qiao, N.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A276 - A276
  • [4] COST-EFFECTIVENESS ANALYSIS (CEA) BETWEEN ERLOTINIB AND GEFITINIB FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN THAILAND
    Prasongsook, Naiyarat
    Jaruhathai, Sureerat
    Maoleekulpairoj, Savitree
    Sooksriwong, Chaoncin
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1245 - S1246
  • [5] Effectiveness and cost of gefitinib in advanced/metastatic non-small cell lung cancer
    Selvi-Sabater, P.
    Sanchez-Martinez, I.
    Sadyrbaeva-Dolgova, S.
    Portillo-Haro, S.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2020, 42 (01) : 289 - 289
  • [6] Impact of clinical and molecular predictors of benefit from erlotinib in advanced non-small cell lung cancer on cost-effectiveness
    Bradbury, P. A.
    Tu, D.
    Seymour, L.
    Ng, R.
    Zhu, L.
    Isogai, P. K.
    Mittmann, N.
    Evans, W. K.
    Shepherd, F. A.
    Leighl, N. B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] COST-EFFECTIVENESS OF THE SECOND LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Chang, C. W.
    Lang, H. C.
    [J]. VALUE IN HEALTH, 2019, 22 : S165 - S166
  • [8] Cost-Effectiveness of Immune Checkpoint Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer
    Kuhlmann, A.
    Schmidt, T.
    Treskova, M.
    Golpon, H.
    Welte, T.
    Von der Schulenburg, J. -Graf
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2302 - S2303
  • [9] COMPARATIVE EFFECTIVENESS AND COST-EFFECTIVENESS ASSESSMENT OF ERLOTINIB VERSUS GEFITINIB IN FIRST-LINE TREATMENT OF EGFR ACTIVATING MUTATION POSITIVE NON-SMALL CELL LUNG CANCER FOR HONG KONG
    Lee, V. W. Y.
    Lee, V
    Schwander, B.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A656 - A656
  • [10] Comparison of gefitinib and erlotinib for Korean patients with advanced non-small cell lung cancer
    Lee, Jin Hwa
    Jo, You Ri
    Park, Hye Sung
    Ryu, Yon Ju
    Chun, Eun Mi
    Chang, Jung Hyun
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S692 - S692
12345